Hepion Pharmaceuticals acquires Gravitas Life Sciences for $2M cash plus 25M shares and names new CEO and CFO

Hepion Pharmaceuticals, Inc.

Hepion acquired all Gravitas Life Sciences membership interests for $2,000,000 cash plus 25,000,000 shares (valued at $2,250,000) and an extra $135,000 payment.
The Purchase Agreement caps issuance at 19.99% of post-issuance outstanding shares, with any reduction settled in cash; shares have a six-month lock-up and piggyback registration rights.
At closing Hepion paid Canton $1,000,000 and GLS paid $125,000 toward the Canton Seller Note; Hepion became sole obligor/guarantor of remaining obligations.
Four Hepion directors, including Stetz and Appajosyula, are GLS officers/Sole Member shareholders and recused themselves; disinterested directors approved with a Ryan Valuation fairness opinion.
Effective Oct. 9, 2026, Sireesh Appajosyula became CEO and Gary Stetz became CFO; Appajosyula was Gravitas Life Sciences' former CEO and Stetz was Hepion's interim CEO.

item 1.01 item 2.01 item 9.01 item 3.02 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sireesh Appajosyula

Chief Executive Officer

HEPA · Hepion Pharmaceuticals, Inc.

Effective: 2026-10-09
Filed: October 9, 2026, 4:30 PM ET

On October 9, 2026, the board of directors (the “Board”) of the Company appointed Gary Stetz, the Company’s former Interim Chief Executive Officer, to serve as the Company’s Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company’s Chief Executive Officer, in each case effective as of October 9, 2026.

Role change

Gary Stetz

Chief Financial Officer

HEPA · Hepion Pharmaceuticals, Inc.

Effective: 2026-10-09
Filed: October 9, 2026, 4:30 PM ET

On October 9, 2026, the board of directors (the “Board”) of the Company appointed Gary Stetz, the Company’s former Interim Chief Executive Officer, to serve as the Company’s Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company’s Chief Executive Officer, in each case effective as of October 9, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sireesh Appajosyula was appointed as Chief Executive Officer at Hepion Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On October 9, 2026, the board of directors (the “Board”) of the Company appointed Gary Stetz, the Company’s former Interim Chief Executive Officer, to serve as the Company’s Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company’s Chief Executive Officer, in each case effective as of October 9, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.85

Gary Stetz was appointed as Chief Financial Officer at Hepion Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On October 9, 2026, the board of directors (the “Board”) of the Company appointed Gary Stetz, the Company’s former Interim Chief Executive Officer, to serve as the Company’s Chief Financial Officer, and Sireesh Appajosyula, PharmD, the former Chief Executive Officer of Gravitas Life Sciences, LLC, to serve as the Company’s Chief Executive Officer, in each case effective as of October 9, 2026.

View on SEC.gov

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-046546

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.